IntelliCyt Announces a New Addition to the iQue® Screener PLUS Platform During CYTO 2016
June 13, 2016
The state-of-the-art iQue Screener PLUS platform is optimized for high throughput and high content functional and phenotypic profiling of single cells in suspension. This new configuration allows researchers to benefit from innovations in reagent and dye technologies and to have more flexibility and choice in experimental design.
Albuquerque, New Mexico – June 13, 2016 – IntelliCyt Corporation, a leading developer of integrated solutions that accelerate drug discovery and life science research, today announced a new addition to the iQue® Screener PLUS platform featuring a 561-nm solid state laser. The iQue Screener platform is an integrated instrument, software, and reagent system that integrates the cell profiling workflow from sample preparation through results. It enables rapid, high content, multiplexed analysis of cells and beads in suspension in 96-, 384-, and 1536-well plates. Its patented sample delivery system, enables rapid plate processing (less than 5 minutes for 96 wells) and assays can be miniaturized to conserve precious sample and use less reagent per well. Software-assisted automation, analysis, and experiment-level visualization tools reveal deep insight into complex biology through an easy-to-use, intuitive interface.
In addition to the standard violet-blue-red laser configuration, the iQue Screener PLUS now offers a violet-yellow-blue laser configuration which opens new avenues of exploration into the complex biology of the immune system and other suspension cells. This new configuration enables researchers to identify, profile, and resolve dim staining populations of interest, with more brightness and less spectral overlap when using Phycoerythrin or Phycoerythrin-tandem dyes. With three lasers and up to 15 detection channels, the iQue Screener PLUS is ideally suited to investigate fluorescent-protein-expressing cells labeled with fluorescent antibodies and functional probes.
“IntelliCyt’s product offering has been successfully applied in antibody discovery, small molecule drug discovery, and for combinatorial profiling in immuno-oncology. We are continuing to address a wider range of applications and are expanding our offering to provide even more capability and flexibility to immunology screening laboratories,” said R. Terry Dunlay, President and CEO of IntelliCyt.
IntelliCyt Corporation manufactures and sells instrumentation, software and reagents that facilitate the study of cells and their components to gain a better understanding of normal and disease processes. This information speeds the discovery and development of new drugs and provides new insight for the diagnosis of diseases. IntelliCyt’s products are used worldwide throughout the pharmaceutical and biotechnology industries and in nonprofit research labs.
To learn more about the iQue Screener PLUS, IntelliCyt Corporation, or to request a quotation, please contact us at 505-345-9075 or visit the website at www.intellicyt.com.